Grant: Operating Grant: Data Analysis Using Existing CDN Databases and Cohorts
McMaster University
$68,700.00
Developing sex-specific predictive models for preeclampsia
EF 2023-24
Résumé
Preeclampsia is a serious multi-system pregnancy complication characterized by high blood pressure in pregnancy after 20 weeks gestation. Preeclampsia occurs in 2-8% of pregnancies worldwide, and can cause devastating short- and long-term adverse health outcomes for both the pregnant individual and fetus.
Preeclampsia occurs more frequently in pregnancies with a female fetus compared to male fetus. However, most studies do not assess sex-specific biomakers for preeclampsia. Currently, there is no consistent method to identify pregnancies at risk of developing preeclampsia.
DNA methylation is a chemical modification made to DNA, that can impact whether the gene is turned on or off. Changes in DNA methylation have been observed in placentas from pregnancies diagnosed with preeclampsia. For this reason, DNA methylation has been gaining interest for use as a biomarker. However, obtaining placental samples during pregnancy is invasive and holds risk for the pregnancy. For this reason, we need a noninvasive means to access placental DNA.
During pregnancy, DNA from the placenta is shed into maternal circulation, where we can quantify it. We will use the novel cell-free methylated DNA immunoprecipitation-sequencing (cfMeDIP-seq) method to non-invasively enrich for placental DNA in pregnant plasma. In the proposed work, we will use DNA methylation information in cell-free placental DNA to (i) characterize sex-specific molecular changes associated with preeclampsia, (ii) identify novel sex-specific subtypes of preeclampsia, and (iii) develop sex-specific prediction model to identify pregnancies at risk of developing preeclampsia.
The proposed research will give valuable insight into sex-specific dynamics in cell-free placental DNA in pregnancies that develop preeclampsia. This work will identify novel sex-specific subtypes of preeclampsia for future follow-up, and develop sex-specific prediction models to identify pregnancies at risk of developing preeclampsia.
Programme
Operating Grant: Data Analysis Using Existing CDN Databases and Cohorts
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
490970
Name
Wilson Samantha L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Data Analysis Using Existing CDN Databases and Cohorts (2026)
Projecttitle
Developing sex-specific predictive models for preeclampsia
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$68,700
Cihrequipment2
$6,300
Programname2
Operating Grant: Data Analysis Using Existing CDN Databases and Cohorts
Keyworddelim
Cell-Free Placental Dna; Machine Learning; Non-Invasive Testing; Prediction Models; Preeclampsia; Sex-Specific
Abstract
Preeclampsia is a serious multi-system pregnancy complication characterized by high blood pressure in pregnancy after 20 weeks gestation. Preeclampsia occurs in 2-8% of pregnancies worldwide, and can cause devastating short- and long-term adverse health outcomes for both the pregnant individual and fetus.
Preeclampsia occurs more frequently in pregnancies with a female fetus compared to male fetus. However, most studies do not assess sex-specific biomakers for preeclampsia. Currently, there is no consistent method to identify pregnancies at risk of developing preeclampsia.
DNA methylation is a chemical modification made to DNA, that can impact whether the gene is turned on or off. Changes in DNA methylation have been observed in placentas from pregnancies diagnosed with preeclampsia. For this reason, DNA methylation has been gaining interest for use as a biomarker. However, obtaining placental samples during pregnancy is invasive and holds risk for the pregnancy. For this reason, we need a noninvasive means to access placental DNA.
During pregnancy, DNA from the placenta is shed into maternal circulation, where we can quantify it. We will use the novel cell-free methylated DNA immunoprecipitation-sequencing (cfMeDIP-seq) method to non-invasively enrich for placental DNA in pregnant plasma. In the proposed work, we will use DNA methylation information in cell-free placental DNA to (i) characterize sex-specific molecular changes associated with preeclampsia, (ii) identify novel sex-specific subtypes of preeclampsia, and (iii) develop sex-specific prediction model to identify pregnancies at risk of developing preeclampsia.
The proposed research will give valuable insight into sex-specific dynamics in cell-free placental DNA in pregnancies that develop preeclampsia. This work will identify novel sex-specific subtypes of preeclampsia for future follow-up, and develop sex-specific prediction models to identify pregnancies at risk of developing preeclampsia.
Competitiondate
202310
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wilson, Samantha L
Approvedterm
1 an 0 mois
Cihrcontribution2
IHDCYH~ $68,700~ $6,300~